Research programme: gene editing based therapeutics - Casebia Therapeutics

Drug Profile

Research programme: gene editing based therapeutics - Casebia Therapeutics

Alternative Names: CRISPR/Cas9 gene editing therapies - Bayer-CRISPR Therapeutics

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Casebia Therapeutics
  • Class Cardiovascular therapies; Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene modulators; Gene transference; Immunogenetic modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Blindness; Congenital heart defects; Haematological disorders; Immunodeficiency disorders

Most Recent Events

  • 17 Apr 2017 Casebia Therapeutics signs a collaboration agreement with StrideBio to develop gene editing based therapeutics
  • 13 Apr 2017 University of California, University of Vienna, and Charpentier appeals decision by PTAB, which dismissed interference proceedings against Broad Institute, MIT, and Harvard University for a patent related to CRISPR-Cas9 genome editing technology, in USA
  • 28 Mar 2017 The European Patent Office announces its intention to grant a patent for CRISPR-Cas9 genome editing technology to University of California, University of Vienna, and Charpentier
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top